Key result
Treatment for acute coronary syndrome significantly improved quality of life compared to baseline (pooled mean difference 31.88; 95% CI 31.64-52.11).
Why the study?
There is little up-to-date evidence regarding changes in quality of life following treatment for patients with ACS.
Do treatments for acute coronary syndrome (PCI, CABG, medical therapy) improve quality of life compared to baseline?
Meta-Analysis
Do treatments for acute coronary syndrome (PCI, CABG, medical therapy) improve quality of life compared to baseline?
Mean Difference: 31.88 (95% CI 31.64–52.11)
Treatment for acute coronary syndrome, including PCI and CABG, significantly improves patient-reported quality of life compared to baseline.
There is little up-to-date evidence about changes in quality of life following treatment for acute coronary syndrome (ACS) patients. The main aim of this review was to assess the changes in QoL in ACS patients after treatment. We undertook a systematic review and meta-analysis of quantitative studies. The search included studies that described the change of QoL of ACS patients after receiving treatment options such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical therapy (MT). We synthesized findings using content analysis and pooled the estimates using meta-analysis. We used the PRISMA guidelines to select and appraise the studies and report the findings. Twenty-nine (29) articles were included in the review. We found a significant improvement of QoL in ACS patients after receiving treatment. Particularly, the meta-analytic association found that the mean QoL of patients diagnosed with ACS was higher after receiving treatment compared to baseline (overall pooled mean difference = 31.88; 95% CI = 31.64–52.11, I2 = 98) with patients on PCI having slightly lower QoL gains (pooled mean difference = 30.22; 95% CI = 29.9–30.53, I2 = 0%) compared to those on CABG (pooled mean difference = 34.01; 95% CI = 33.66–34.37, I2 = 0%). The review confirmed that QoL of ACS patients improved after receiving treatment therapies although varied by the treatment options and patients’ preferences. This suggests the need to perform further study on the QoL, patient preferences and physicians’ decision to prescription of treatment options.
No takes yet. Share an insight, caveat, or question.
Kaambwa et al. (2020) conducted a meta-analysis in Acute coronary syndrome (ACS). Treatment (PCI, CABG, and medical therapy) vs. Baseline was evaluated on Change in quality of life (QoL) (MD 31.88, 95% CI 31.64-52.11). Treatment for acute coronary syndrome significantly improved quality of life compared to baseline (pooled mean difference 31.88; 95% CI 31.64-52.11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: